Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 10 of 431

Publication Record

Connections

Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer.
Morgans AK, Shore N, Cope D, McNatty A, Moslehi J, Gomella L, Sartor O
(2021) Urol Oncol 39: 52-62
MeSH Terms: Androgen Antagonists, Cardiovascular Diseases, Drug Interactions, Humans, Male, Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant, Risk Assessment, Risk Factors
Added September 29, 2020
0 Communities
1 Members
0 Resources
9 MeSH Terms
Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses.
Hu JR, Duncan MS, Morgans AK, Brown JD, Meijers WC, Freiberg MS, Salem JE, Beckman JA, Moslehi JJ
(2020) Arterioscler Thromb Vasc Biol 40: e55-e64
MeSH Terms: Androgen Antagonists, Antineoplastic Agents, Hormonal, Cardiotoxicity, Cardiovascular Diseases, Cardiovascular System, Humans, Male, Prostatic Neoplasms, Risk Assessment, Risk Factors, Treatment Outcome
Added May 29, 2020
0 Communities
2 Members
0 Resources
11 MeSH Terms
Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group.
Narayan V, Harrison M, Cheng H, Kenfield S, Aggarwal R, Kwon D, McKay R, Hauger R, Hart N, Conzen S, Borno H, Jim H, Dicker A, Dorff T, Moslehi J, Mucci L, Parsons JK, Saad F, Soule H, Morgans A, Ryan CJ
(2020) Urol Oncol 38: 83-93
MeSH Terms: Biomedical Research, Cancer Survivors, Continuity of Patient Care, Humans, Male, Prostatic Neoplasms, Survival Rate
Added January 15, 2020
0 Communities
1 Members
0 Resources
7 MeSH Terms
Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study.
Bretagne M, Lebrun-Vignes B, Pariente A, Shaffer CM, Malouf GG, Dureau P, Potey C, Funck-Brentano C, Roden DM, Moslehi JJ, Salem JE
(2020) Arch Cardiovasc Dis 113: 9-21
MeSH Terms: Adverse Drug Reaction Reporting Systems, Aged, Aged, 80 and over, Androgen Antagonists, Androstenes, Antineoplastic Agents, Hormonal, Cardiotoxicity, Databases, Factual, Heart Failure, Humans, Male, Middle Aged, Pharmacovigilance, Phenylthiohydantoin, Prostatic Neoplasms, Retrospective Studies, Risk Assessment, Risk Factors, Tachycardia, Supraventricular, Time Factors
Added November 12, 2019
0 Communities
2 Members
0 Resources
20 MeSH Terms
Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer.
Dudzinski SO, Cameron BD, Wang J, Rathmell JC, Giorgio TD, Kirschner AN
(2019) J Immunother Cancer 7: 218
MeSH Terms: Animals, Disease Models, Animal, Humans, Immunotherapy, Male, Mice, Prostatic Neoplasms, Castration-Resistant
Added March 3, 2020
0 Communities
1 Members
0 Resources
7 MeSH Terms
Radiosensitization by enzalutamide for human prostate cancer is mediated through the DNA damage repair pathway.
Sekhar KR, Wang J, Freeman ML, Kirschner AN
(2019) PLoS One 14: e0214670
MeSH Terms: Aged, Animals, Cell Line, Tumor, Cell Proliferation, DNA Damage, DNA Repair, Drug Resistance, Neoplasm, Humans, Male, Mice, Mice, Nude, Mice, Transgenic, Phenylthiohydantoin, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Radiation Tolerance, Radiation-Sensitizing Agents, Signal Transduction, Xenograft Model Antitumor Assays
Added April 2, 2019
0 Communities
2 Members
0 Resources
19 MeSH Terms
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies.
Kaiser A, Eley JG, Onyeuku NE, Rice SR, Wright CC, McGovern NE, Sank M, Zhu M, Vujaskovic Z, Simone CB, Hussain A
(2019) J Vis Exp :
MeSH Terms: Humans, Male, Photons, Prostatic Neoplasms, Proton Therapy, Radiometry, Radiotherapy Planning, Computer-Assisted
Added March 30, 2020
0 Communities
1 Members
0 Resources
MeSH Terms
Emerin Deregulation Links Nuclear Shape Instability to Metastatic Potential.
Reis-Sobreiro M, Chen JF, Novitskaya T, You S, Morley S, Steadman K, Gill NK, Eskaros A, Rotinen M, Chu CY, Chung LWK, Tanaka H, Yang W, Knudsen BS, Tseng HR, Rowat AC, Posadas EM, Zijlstra A, Di Vizio D, Freeman MR
(2018) Cancer Res 78: 6086-6097
MeSH Terms: Animals, Apoptosis, Biomarkers, Tumor, Cell Line, Tumor, Cell Movement, Cell Nucleus, Disease Progression, Gene Expression Regulation, Neoplastic, Humans, Male, Membrane Proteins, Mice, Mice, SCID, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplastic Cells, Circulating, Nuclear Envelope, Nuclear Proteins, Prostatic Neoplasms
Added April 10, 2019
0 Communities
1 Members
0 Resources
19 MeSH Terms
Quantitative in vivo whole genome motility screen reveals novel therapeutic targets to block cancer metastasis.
Stoletov K, Willetts L, Paproski RJ, Bond DJ, Raha S, Jovel J, Adam B, Robertson AE, Wong F, Woolner E, Sosnowski DL, Bismar TA, Wong GK, Zijlstra A, Lewis JD
(2018) Nat Commun 9: 2343
MeSH Terms: Animals, Cell Line, Tumor, Cell Movement, Chick Embryo, Collagen, Female, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Humans, Male, Mice, Mice, Nude, Mice, SCID, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasm Transplantation, Phenotype, Prostatic Neoplasms, RNA Interference, RNA, Small Interfering
Added April 10, 2019
0 Communities
1 Members
0 Resources
MeSH Terms
MAGI2 is an independent predictor of biochemical recurrence in prostate cancer.
David SN, Arnold Egloff SA, Goyal R, Clark PE, Phillips S, Gellert LL, Hameed O, Giannico GA
(2018) Prostate 78: 616-622
MeSH Terms: Adaptor Proteins, Signal Transducing, Adenocarcinoma, Aged, Carrier Proteins, Disease Progression, Gene Expression, Guanylate Kinases, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Predictive Value of Tests, Prognosis, Prostate-Specific Antigen, Prostatic Neoplasms
Added March 30, 2020
0 Communities
1 Members
0 Resources
15 MeSH Terms